This article's lead is ready for translation. Click for more information.

Necitumumab

From WikiProjectMed
Jump to navigation Jump to search
Necitumumab
Necitumumab Fab (blue) bound to EGFR (green). PDB: 6B3S​
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetEGFR
Names
Trade namesPortrazza
Clinical data
Main usesSquamous-cell cancer of the lung[1]
Side effectsRash, low magnesium[2]
Routes of
use		Intravenous infusion
Typical dose800 mg[2]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Pharmacokinetics
Elimination half-life~14 days
Chemical and physical data
FormulaC6436H9958N1702O2020S42
Molar mass144844.87 g·mol−1

Necitumumab, sold under the brand name Portrazza, is a medication used for non-small-cell lung carcinoma (NSCLC).[1] Specifically it is used, together with gemcitabine and cisplatin, for squamous-cell cancer of the lung that has spread.[1] Such use; however, is not recommended in the United Kingdom.[3] It is given by gradual injection into a vein.[2]

Common side effects include rash and low magnesium.[2] Other side effects may include cardiac arrest and blood clots.[2] Use in pregnancy may harm the baby.[2] It is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR).[3]

Necitumumab was approved for medical use in the United States in 2015.[1] While it was approved for use in Europe in 2016, this approval was subsequently withdrawn.[4] In the United Kingdom it cost the NHS £1,450 per dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[5]

Medical uses

It was counterproductive in non-squamous non-small-cell lung carcinoma.[6][7]

Dosage

The typical dose is 800 mg on day 1 and 8 out of 21 days.[2]

Mechanism of action

Mechanism of necitumumab[8]

The mode of action of Necitumumab is via binding to the EGFR, which prevents the binding of its ligands. This in turn causes receptor internalization and degradation. Finally this causes inhibition of proliferation and survival[8]

References

  1. ↑ 1.0 1.1 1.2 1.3 "Necitumumab Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 12 November 2021. Archived 4 March 2021 at the Wayback Machine
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "DailyMed - PORTRAZZA- necitumumab solution". dailymed.nlm.nih.gov. Archived from the original on 9 August 2021. Retrieved 12 November 2021. Archived 9 August 2021 at the Wayback Machine
  3. ↑ 3.0 3.1 3.2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 920. ISBN 978-0857114105.
  4. ↑ "Portrazza". Archived from the original on 7 August 2021. Retrieved 12 November 2021. Archived 7 August 2021 at the Wayback Machine
  5. ↑ "Portrazza Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 12 November 2021. Archived 26 February 2021 at the Wayback Machine
  6. ↑ "Portrazza: Highlights of Prescribing Information" (PDF). www.accessdata.fda.gov. 2015. Archived (PDF) from the original on 2020-09-30. Retrieved 2019-09-28. Archived 2020-09-30 at the Wayback Machine
  7. ↑ Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25. Archived 2015-11-29 at the Wayback Machine
  8. ↑ 8.0 8.1 Seebacher, N. A.; Stacy, A. E.; Porter, G. M.; Merlot, A. M. (11 April 2019). "Clinical development of targeted and immune based anti-cancer therapies". Journal of Experimental & Clinical Cancer Research. 38 (1): 156. doi:10.1186/s13046-019-1094-2. ISSN 1756-9966. Archived from the original on 25 June 2024. Retrieved 21 June 2024.{{cite journal}}: CS1 maint: unflagged free DOI (link) Archived 25 June 2024 at the Wayback Machine

External links

Identifiers:

Stub icon

This monoclonal antibody–related article is a stub. You can help MDWiki by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Necitumumab&oldid=1468449"